The Tisch Cancer Institute

Center for Novel Therapeutics

Key to advancing optimal cancer care-the overarching mission of The Tisch Cancer Institute (TCI)-is the pursuit of novel therapies based on scientific investigation that lead to the most effective care with the best outcomes and minimal adverse events.

The Novel Therapeutics/Phase I Center (center) at TCI, under the leadership of medical director Matthew Galsky, MD, Professor of Medicine, facilitates early phase clinical trials designed to maximize the development of cutting-edge therapies. With an emphasis on first-in-human and biomarker focused proof-of-concept studies. The center promotes the translation of scientific discoveries from TCI laboratories to clinical applications that may favorably impact patient outcomes. New drugs may be piloted or combined in novel fashions or administered in ways that are hypothesized to be more effective, such as injection directly into tumors.

The center facilitates TCI's rapid progress in cancer immunotherapy and serves as a hub for precision medicine clinical trials by fostering seamless integration of oncology, genomics, computational biology, pathology, interventional and diagnostic radiology, and medical and surgical specialties.

Meet Our Team

Matthew Galsky, MD
Medical Director
Matthew.galsky@mssm.edu

Lynn Bui, MS
Project Manager
Lynn.bui@mssm.edu

Thomas Marron, MD
Immunotherapy
Thomas.marron@mssm.edu

Nina Bhardwaj, MD
Immunotherapy
Nina.bhardwaj@mssm.edu

Joshua Brody, MD
Immunotherapy
Joshua.brody@mssm.edu